Search results for "biological factor"
showing 10 items of 74 documents
Carotenoids
2009
Publisher Summary This chapter provides an overview of what is known about carotenoid metabolism in Chlamydomonas with reference to other green algae and vascular plants. The biosynthesis of carotenoids and the subdivisions of carotenogenesis are described. With respect to subcellular distribution, the carotenoids in vegetative cells localize to the chloroplast where they either serve as photosynthetic pigments bound to the protein complexes of the two photosystems, or as components of the eyespot apparatus is outlined with its functional significance. Carotenoids can serve as precursors of a number of other molecules with important physiological functions in Chlamydomonas.
Carotenoids and the Assembly of Light-harvesting Complexes
2006
Carotenoids are constitutive components of all light-harvesting complexes in plants and many such complexes in bacteria. In the crystal structures of several light-harvesting complexes, carotenoids are seen to span the lipid bilayer and connect components of the complex on both membrane surfaces and/or to mediate the interaction of transmembrane protein helices. This important stabilizing function suggests that these pigments are also actively involved in the assembly of light-harvesting complexes. Verification of this notion appears too ambitious a goal at present, as the question of how the pigment-protein complexes of the photosynthetic apparatus are assembled is still open. However, inf…
Antibody recognition of fluorinated MUC1 glycopeptide antigens.
2011
The syntheses of various fluorinated MUC1 glycopeptide antigens and their specific binding to serum antibodies from mice immunized with natural and fluorinated TF(6)-MUC1-TTox conjugate vaccines are presented.
Synthesis of a MUC1-glycopeptide-BSA conjugate vaccine bearing the 3'-deoxy-3'-fluoro-Thomsen-Friedenreich antigen.
2011
A novel MUC1-glycopeptide–BSA conjugate vaccine with a specifically fluorinated Thomsen–Friedenreich antigen side chain at Thr6 was prepared. Preliminary immunological experiments reveal specific binding of the tumor-associated glycopeptide antigen analog by anti-MUC1-mouse antibodies.
Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies
2015
We have developed a highly versatile platform for the systematic retrieval of T-cell receptors (TCRs) from single-antigen-reactive T cells and for characterization of their function and specificity. This approach enables rapid extraction of multiple TCRs from repertoires in individuals and not only broadens the diversity of TCRs suitable for clinical use, but also sets the stage for actively personalized immunotherapeutic strategies.
Mucin 1 downregulation associates with corticosteroid resistance in chronic rhinosinusitis with nasal polyps
2013
Background A number of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) are resistant to oral corticosteroids. Mucin 1 (MUC1) shows anti-inflammatory properties, and its cytoplasmic tail (CT) interacts with transcription factors, facilitating their nuclear translocation. Because glucocorticoid receptor (GR) nuclear translocation is key to the anti-inflammatory effect of corticosteroids, we hypothesized that MUC1 is involved in the effectiveness of corticosteroids. Objective To analyze the role of MUC1 in corticosteroid effectiveness in different cohorts of patients with CRSwNP and elucidate the possible mechanisms involved. Methods Seventy-three patients with CRSwNP took oral…
Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum
2019
Introduction: Pyoderma gangrenosum (PG) is a noninfectious, reactive inflammatory neutrophilic dermatosis that is commonly associated with autoimmune and neoplastic disorders. There are emerging diagnostic tools and treatment options for PG.Area covered: The diagnosis of PG should be seriously considered when managing ulcers to avoid unnecessary medical and surgical complications with prompt and suitable treatment. There are no standardized treatment guidelines for PG, and current therapy largely depends on the severity and progression of the disease. Systemic corticosteroids, immunosuppressant therapy, and biologic agents remain mainstay therapies. In this article, we present a literature …
Comparing medical treatments for Crohn’s disease
2013
The drugs available for inflammatory bowel disease are aminosalicylates, antibiotics, steroids, immunosuppressors and biologics. The effectiveness of these drugs has been evaluated in many randomized clinical trials, mainly versus placebo. Few studies have been conducted comparing the different drugs among themselves, owing to the methodological problems raised by comparative trials, such as sample size and blindness. This review focuses mainly on the randomized clinical trials that have compared different treatments. Of course comparisons are mainly between drugs used in a particular setting (mild, moderate and severe disease). However, on many occasions there is no homogeneity in these cl…
Pentobarbital-sensitive EDHF comediates ACh-induced arteriolar dilation in the hamster microcirculation
1999
It is unclear to what extent the endothelium-derived hyperpolarizing factor (EDHF) contributes to the control of microcirculatory blood flow in vivo. We analyzed, by intravital microscopy in hamster muscles, the potential role of EDHF along the vascular tree under stimulated (ACh) or basal conditions. Experiments were performed in conscious as well as anesthetized (pentobarbital, urethan) animals. Additionally, cellular effects of the potential EDHF were studied in isolated small arteries. In pentobarbital-anesthetized animals, treatment with N ω-nitro-l-arginine (l-NNA; 30 μmol/l) and indomethacin (3 μmol/l) reduced the dilation in response to 10 μmol/l ACh from 60 ± 6 to 20 ± 4%. This ni…
S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 2.
2019
The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology, pediatrics, pediatric dermatology and pediatric rheumatology as well as policymakers and insurance funds. They were developed by dermatologists and pediatric dermatologists in collaboration with pediatric rheumatologists using a formal consensus process (S2k). The guidelines highlight topics such as disease severity, quality of life, treatment goals as well as problems associated with off-label drug therapy in children. Trigger factors and diagnostic aspects are discussed. The primary focus is on the various topical, systemic and UV-based treatment options available and includes recomm…